
Is Surgery for Ulcerative Colitis (UC) Right for you?
Surgery for ulcerative colitis (UC) is considered when medication and diet changes are ineffective, with about 9.2% of patients eventually undergoing colectomy. Common surgeries include proctocolectomy, ileostomy, and ileal pouch-anal anastomosis (IPAA).
After surgery, you may need an ileostomy or an ileoanal pouch to manage waste. Recovery and adaptation to life post-surgery require medical support and patient education.
Surgery can significantly improve quality of life and eliminate symptoms for many patients. Long-term follow-up is essential to monitor for potential complications. It's important to discuss all the options fully with your doctor to decide if this option is right for you.
Surgery is one of the many treatment options available for people with ulcerative colitis (UC). However, not everyone with this condition will need surgery.
You may be able to manage UC through medication and changes to your diet. Over time, the initial treatments your doctor prescribed may no longer work, or they may become less effective.
How many people have surgery?
In a 2018 study of Swiss people with UC, researchers found that 9.2% of the study participants eventually underwent colectomy (colon removal). They also found that:
5 years after diagnosis, 4.1 percent of people had received a colectomy
10 years after diagnosis, 6.4 percent of people had received a colectomy
15 years after diagnosis, 10.4 percent of people had received a colectomy
20 years after diagnosis, 14.4 percent of people had received a colectomy
Most people had their colectomies performed within 10 years of being diagnosed. Surgery rates for people who'd lived with UC for at least 15 years were significantly lower than rates for people who'd been diagnosed more recently.
Ileostomy
After having UC surgery, your doctor will need to create a way for your body to eliminate waste.
A procedure known as an ileostomy can help. In an ileostomy, your ileum (the final section of the small intestine) is connected to your abdominal wall.
You'll need a stoma as part of the procedure. A stoma is a surgically created opening that allows waste from your intestines to exit your body. A stoma is typically made in the lower abdomen, just below the waist.
Proctocolectomy
Proctocolectomy is the most common type of UC surgery.
A proctocolectomy is performed in the hospital as an inpatient operation. This means you'll stay in the hospital during the procedure and for part of your recovery. You'll need to receive general anesthesia.
After you have a proctocolectomy, you'll also need an ileostomy or an ileal pouch-anal anastomosis (IPAA) to help you eliminate waste.
In most cases, your doctor will conduct both procedures on the same day so you don't have to have general anesthesia again.
In a total proctocolectomy, the anus is also removed.
Ileal pouch-anal anastomosis (IPAA)
Ileal pouch-anal anastomosis (IPAA) is sometimes called a J-pouch surgery. In this procedure, the ileum is converted into a pouch shaped like the letter 'J.' The pouch is then connected to your anal canal.
IPAA is usually effective, but it hasn't been around as long as ileostomy has. This means it may be more difficult to find a surgeon who can perform the procedure.
This procedure is typically performed in two or three stages over the course of 2 or 3 months. You may receive a temporary ileostomy while your pouch heals.
What to expect
As with the ileostomy, you'll need a proctocolectomy before an IPAA. An IPAA is performed in a hospital, and you'll receive general anesthesia.
The IPAA won't function like a normal bowel and rectum at first. You may have bowel leakage for several weeks while you learn to control the internal pouch. Medications may help control the function of the pouch.
If you're planning to give birth to children in the future, talk with your doctor about this before the procedure. This procedure may lead to infertility in some people.
Continent ileostomy
Another type of ileostomy is continent ileostomy or K-pouch surgery. The K-pouch is also known as a Kock pouch, hence its name.
During this procedure, the end of your ileum is secured against the inside of your abdomen.
Unlike a traditional ileostomy, you don't need to wear an ostomy bag. A K-pouch is also different from a J-pouch in that the ileum isn't connected with the anus. Instead, a continent ileostomy relies on an internal human-made valve that collects waste and prevents the waste from draining out.
When the K-pouch gets full, waste is removed via a catheter. You'll need to use a stoma cover and drain the pouch often, at least a few times per day.
After your UC surgery, you'll stay in the hospital for 3 to 7 days. This window of time allows your surgeon to monitor you for signs of complications.
Both ileostomies and pouch surgeries will require a 4- to 6-week recovery period.
During this time, you'll meet regularly with your surgeon, doctor, and possibly an enterostomal therapist.
An enterostomal therapist is a specialized therapist who works directly with people who've had their colon removed.
Your care team will likely cover the following points with you to help improve your recovery:
Eat well: Good nutrition can help your body heal and help you avoid post-operation health issues. Nutrition absorption can be an issue after these surgeries, so eating well will help you maintain healthy levels of nutrients.
Hydrate: Hydration is important for your overall health but especially for your digestive health. Drink six to eight glasses per day at a minimum.
Stay active: Work with a rehab therapist or a physical therapist to slowly recover your physical capabilities, and exercise when you can. Staying active is a great way to care for your overall health as you recover, but too much activity too soon could complicate your recovery.
Manage stress: Anxiety or emotional stress can cause stomach issues, which can increase your risk of an accident.
Surgery risks
Surgery is usually a last-resort option for UC, partly due to the fact that any surgery can pose risks and complications. Some of the risks of UC surgery include:
bleeding
infection
scarring
itching or irritation of the stoma
organ damage
blocked intestines from scar tissue buildup
diarrhea
excessive gas
rectal discharge
nutritional deficiencies, especially vitamin B12
electrolyte imbalances
Bowel surgery may also increase your risk of developing phantom rectum. A phantom rectum refers to the feeling of having to pass a bowel movement even though you no longer have a rectum. This can occur for several years postsurgery.
Meditation, antidepressants, and over-the-counter (OTC) pain relievers may help with phantom rectum.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Market Surges Amid Rising Liver Disease and Cancer Prevalence
The global ascites market is experiencing significant growth, driven by the rising prevalence of liver diseases, cancers, and other risk factors like alcohol consumption and hepatitis infections. Key advancements in diagnostic technologies, such as ultrasound and CT scans, are enhancing early detection and treatment options. Despite growth, challenges like high treatment costs and potential side effects hinder market expansion, particularly in developing regions. Leading companies, including Ocelot Bio and Regeneron Pharmaceuticals, are innovating to improve treatment efficacy. With increasing demand in emerging markets and an aging population, the ascites market is set for sustained growth. Dublin, July 14, 2025 (GLOBE NEWSWIRE) -- The "Ascites Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to ascites market is witnessing substantial growth, driven by a range of key factors. One of the primary drivers for the ascites market is the rising prevalence of liver diseases, particularly cirrhosis, as well as various forms of cancer, such as liver, ovarian, and pancreatic cancer. As these diseases are among the leading causes of ascites, their increasing incidence globally is driving the demand for diagnostic tools and treatment options. The global rise in lifestyle diseases, alcohol consumption, and hepatitis infections has contributed to this increase, which in turn propels the growth of the ascites market. As the ascites market continues to evolve, several emerging trends are expected to significantly influence its future trajectory. The aging global population is another significant factor driving the ascites market. Older adults are more prone to liver diseases, heart failure, and cancer, all of which are major risk factors for ascites. As the number of elderly individuals increases, the prevalence of ascites is expected to rise, further driving the demand for effective treatments and management strategies. Leading players in the global ascites market, such as Ocelot Bio, Regeneron Pharmaceuticals, and BioVie Inc., are continuously focusing on several strategies to maintain their competitive edge and drive growth. These strategies include continuous technological innovation, such as the development of more advanced and efficient treatment options, mapping systems, and imaging technologies. These companies aim to enhance the safety and efficacy of ascites treatment competitive landscape of the global ascites market is diverse, with numerous players across different regions offering a wide range of products. Regional players and local manufacturers are expected to play an important role in the market's growth, especially as demand increases in emerging markets such as Asia-Pacific and Latin America. As consumer preferences shift towards more discreet, comfortable, and affordable solutions, the ascites market will continue to evolve, fostering new opportunities for both established and emerging the development and improvement of diagnostic technologies, including imaging techniques like ultrasound, CT scans, and the use of paracentesis for fluid analysis, are major drivers for the ascites market. Early detection and accurate diagnosis allow for timely intervention, improving treatment outcomes. The availability of non-invasive and highly sensitive diagnostic tests increases the likelihood of diagnosing ascites in its early stages, expanding the demand for related treatment and management the positive growth trajectory, several challenges continue to impact the global ascites market. One of the primary challenges is the high cost of treatments, particularly for advanced interventions such as liver transplants, chemotherapy, and some novel drug therapies. These costs can be a significant barrier to access, especially in developing regions where healthcare infrastructure may be limited, and insurance coverage for expensive treatments may not be available. This high cost can restrict the market growth, as many patients may not be able to afford the necessary side effects and complications of treatment further restrict the market growth. Several treatments for ascites, including diuretics and paracentesis, can lead to complications or side effects, such as electrolyte imbalances, infections, or low blood pressure. These potential risks may deter patients from seeking treatment or adhering to prescribed regimens, thus limiting the overall demand for these interventions. Additionally, the invasive nature of some treatments, such as the need for repeated paracentesis, can be uncomfortable for patients and may result in decreased willingness to pursue these conclusion, the global ascites market is expected to see steady growth, driven by the increasing prevalence of underlying conditions such as liver diseases and cancers, as well as advancements in diagnostic and therapeutic options. Continued research and innovation in targeted treatments, along with a growing focus on early detection, will be key to improving patient outcomes and reducing the burden of ascites on healthcare systems. As stakeholders, including pharmaceutical companies, healthcare providers, and researchers, continue to work toward better management strategies, the market will evolve to offer more effective solutions, ultimately enhancing the quality of life for patients and addressing the ongoing challenges posed by this Topics Covered: 1. Global Ascites Markets: Industry Outlook1.1 Introduction1.2 Market Trends1.3 Regulatory Framework1.4 Epidemiology of Ascites1.5 Clinical Trial Analysis1.6 Market Dynamics1.6.1 Impact Analysis1.6.2 Market Drivers1.6.3 Market Challenges1.6.4 Market Opportunities2. Global Ascites Market, by Region, $Million, 2023-20352.1 North America2.1.1 Key Findings2.1.2 Market Dynamics2.1.3 Market Sizing and Forecast2.1.3.1 North America Ascites Market, by Country2.1.3.1.1 U.S.2.2 Europe2.2.1 Key Findings2.2.2 Market Dynamics2.2.3 Market Sizing and Forecast2.2.3.1 Europe Ascites Market, by Country2.2.3.1.1 Germany2.2.3.1.2 U.K.2.2.3.1.3 France2.2.3.1.4 Italy2.2.3.1.5 Spain2.3 Asia Pacific2.3.1 Key Findings2.3.2 Market Dynamics2.3.3 Market Sizing and Forecast2.3.3.1 Asia Pacific Ascites Market, by Country2.3.3.1.1 Japan3. Global Ascites Market: Competitive Landscape and Company Profiles3.1 Key Development and Strategies3.1.1 Mergers and Acquisitions3.1.2 Synergistic Activities3.1.3 Business Expansions and Funding3.1.4 Product Launches and Approvals3.1.5 Other Activities3.2 Company Profiles3.2.1 Ocelot Bio3.2.1.1 Overview3.2.1.2 Top Products / Product Portfolio3.2.1.3 Target Customers/End-Users3.2.1.4 Key Personnel3.2.1.5 Analyst View3.2.2 PharmaIN3.2.3 Grifols Therapeutics LLC.3.2.4 Regeneron Pharmaceuticals.3.2.5 BioVie Inc4. Research Methodology For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Market to Reach $14.34 Billion by 2034, Driven by Innovative R&D, Strategic Collaborations, and Drug Formulation Advancements
The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by rising diabetes and obesity rates, innovative drug formulations, and supportive healthcare policies, the market is expanding. Key players include Eli Lilly, Sanofi, and Novo Nordisk. Challenges involve high costs and regulatory complexities. Opportunities lie in obesity treatment expansion and advanced drug delivery systems. European Glucagon-like Peptide-1 (GLP-1) Agonists Market Dublin, July 14, 2025 (GLOBE NEWSWIRE) -- The "Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Report and Forecast 2025-2034" has been added to offering. The Europe glucagon-like peptide-1 (GLP-1) agonists market is projected to witness significant growth, fueled primarily by an increased prevalence of type 2 diabetes and obesity. Originally valued at USD 7.09 billion in 2024, the market is estimated to expand at a compound annual growth rate (CAGR) of 17.30%, expecting a valuation of USD 14.34 billion by 2034. The competitive landscape features major pharmaceutical firms like Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca, and others focused on innovative R&D, strategic collaborations, and drug formulation advancements. These companies aim to enhance market presence through mergers, acquisitions, and partnerships that promote access and compliance, ensuring sustained growth in the Europe's GLP-1 agonists market. The market's expansion is propelled by the increasing incidence of diabetes and obesity, augmented by sedentary lifestyles and poor dietary choices. GLP-1 agonists, as incretin-based therapies, are preferred for their efficacy in controlling blood sugar levels and facilitating weight loss, crucial aspects in managing diabetes and obesity. The growth trajectory is supported by rising healthcare expenditure, a burgeoning elderly demographic, advancements in drug delivery, and a robust regulatory framework favoring novel therapeutic adoption. Key Attributes: Report Attribute Details No. of Pages 300 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $7.09 Billion Forecasted Market Value (USD) by 2034 $14.34 Billion Compound Annual Growth Rate 7.3% Regions Covered Europe Market Drivers A surge in type 2 diabetes and obesity cases. Favorable government initiatives and reimbursement policies bolstering access to innovative treatments. Improved drug formulations like once-weekly injectables and oral options enhancing patient compliance. A growing trend towards combination therapies integrating GLP-1 agonists for optimized results. Market Challenges High costs of GLP-1 therapies affecting widespread accessibility. Potential side effects that could hinder patient adherence. Regulatory complexities delaying new therapy commercializations. Future Opportunities Expanding applications in obesity treatment beyond diabetes management. Innovative drug delivery system developments heightening market penetration. Strategic R&D investments for next-gen GLP-1 therapies with enhanced efficacy. Europe GLP-1 Agonists Market Trends The shift towards long-acting GLP-1 formulations like once-weekly injections elevating patient compliance. The increasing use of GLP-1 agonists in obesity management, supported by regulatory endorsements. Clinical validation of cardiovascular benefits driving GLP-1 adoption among patients at cardiovascular risk. Policymaker efforts in expanding healthcare coverage improving treatment accessibility. The development of multi-target GLP-1 therapies promises superior management of diabetes and weight issues. Strategic collaborations in biosimilar production broadening market access and affordability. Market Segmentation By Drugs: Key drugs include dulaglutide, exenatide, liraglutide, tirzepatide, lixisenatide, and semaglutide. By Application: The applications span type 2 diabetes mellitus and obesity treatment. By Route of Administration: Dominated by parenteral routes, the market is gradually seeing a rise in oral solution adoption. By End User: Primary users are hospitals, specialty clinics, academic research sites, with home care settings gaining traction. By Distribution Channel: Hospital pharmacies prevail, while retail and online pharmacies steadily gain ground. By Region: The United Kingdom, Germany, France, and Italy emerge as principal markets, bolstered by strong infrastructure and supportive policies. Companies Featured Eli Lilly and Company Sanofi Novo Nordisk A/S AstraZeneca plc For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment European Glucagon-like Peptide-1 (GLP-1) Agonists Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio


Washington Post
an hour ago
- Washington Post
As a gastroenterologist, here's what I eat in a day to boost my gut health
You talk a lot about how important it is to eat a high-fiber diet but that most Americans don't meet their daily recommended fiber goals. I'm curious what you personally do to reach that goal. Many of my patients automatically picture a 'high-fiber diet' as a life of kale salads and never seeing a slice of white toast again.